KalVista Pharmaceuticals’ (KALV) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV – Get Rating) in a research report report published on Friday morning, Benzinga reports. HC Wainwright currently has a $16.00 price objective on the specialty pharmaceutical company’s stock.

KALV has been the topic of several other reports. SVB Leerink lowered their target price on KalVista Pharmaceuticals from $30.00 to $20.00 and set an outperform rating on the stock in a report on Friday, February 3rd. Needham & Company LLC restated a buy rating and issued a $22.00 price objective (down previously from $24.00) on shares of KalVista Pharmaceuticals in a research note on Thursday, March 9th.

KalVista Pharmaceuticals Price Performance

Shares of KALV stock opened at $7.49 on Friday. The business has a fifty day moving average of $7.55 and a 200 day moving average of $8.00. The firm has a market capitalization of $184.40 million, a price-to-earnings ratio of -2.10 and a beta of 1.12. KalVista Pharmaceuticals has a 1 year low of $4.12 and a 1 year high of $17.06.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Thomas Andrew Crockett sold 6,700 shares of the company’s stock in a transaction dated Friday, February 17th. The shares were sold at an average price of $7.66, for a total value of $51,322.00. Following the completion of the transaction, the chief executive officer now owns 120,927 shares in the company, valued at approximately $926,300.82. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 3,412 shares of the company’s stock in a transaction that occurred on Friday, February 17th. The shares were sold at an average price of $7.66, for a total value of $26,135.92. Following the transaction, the insider now owns 9,347 shares in the company, valued at approximately $71,598.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Thomas Andrew Crockett sold 6,700 shares of the company’s stock in a transaction that occurred on Friday, February 17th. The shares were sold at an average price of $7.66, for a total transaction of $51,322.00. Following the completion of the transaction, the chief executive officer now owns 120,927 shares in the company, valued at approximately $926,300.82. The disclosure for this sale can be found here. In the last 90 days, insiders sold 15,066 shares of company stock valued at $115,406. Insiders own 8.30% of the company’s stock.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its position in shares of KalVista Pharmaceuticals by 24.9% during the 1st quarter. JPMorgan Chase & Co. now owns 13,424 shares of the specialty pharmaceutical company’s stock worth $198,000 after buying an additional 2,677 shares during the period. Bank of New York Mellon Corp increased its holdings in KalVista Pharmaceuticals by 5.8% during the first quarter. Bank of New York Mellon Corp now owns 69,570 shares of the specialty pharmaceutical company’s stock worth $1,026,000 after buying an additional 3,838 shares during the last quarter. MetLife Investment Management LLC increased its holdings in shares of KalVista Pharmaceuticals by 103.8% in the first quarter. MetLife Investment Management LLC now owns 12,495 shares of the specialty pharmaceutical company’s stock valued at $184,000 after purchasing an additional 6,365 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of KalVista Pharmaceuticals by 16.3% in the first quarter. Rhumbline Advisers now owns 22,150 shares of the specialty pharmaceutical company’s stock valued at $326,000 after purchasing an additional 3,100 shares during the last quarter. Finally, BlackRock Inc. boosted its position in shares of KalVista Pharmaceuticals by 2.6% in the first quarter. BlackRock Inc. now owns 1,544,027 shares of the specialty pharmaceutical company’s stock valued at $22,757,000 after acquiring an additional 39,407 shares during the period.

KalVista Pharmaceuticals Company Profile

(Get Rating)

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.